Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04252118 |
|
Recruitment Status :
Recruiting
First Posted : February 5, 2020
Last Update Posted : April 15, 2020
|
Sponsor:
Beijing 302 Hospital
Collaborators:
Innovative Precision Medicine Group (IPM), Hangzhou, China.
Huoshenshan Hospital
Tianjin Haihe Hospital
VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China
Shenzhen Third People's Hospital
Fifth Affiliated Hospital, Sun Yat-Sen University
Information provided by (Responsible Party):
Fu-Sheng Wang, Beijing 302 Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2020 |
| Estimated Study Completion Date : | December 2021 |